Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy’s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases - Allele Capital

https://ir.coyatherapeutics.com/news/news-details/2023/Coya-Therapeutics-Inc.-Announces-an-Agreement-with-Dr.-Reddys-Laboratories-Ltd.-to-License-its-proposed-biosimilar-Abatacept-for-the-Development-and-Commercialization-of-COYA-302-for-the-Treatment-of-Neurodegenerative-Diseases/default.aspx